{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T21:53:44Z","timestamp":1784238824887,"version":"3.55.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Ordos Health Commission Key Discipline Project."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"DOI":"10.1186\/s40360-025-00964-6","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T10:25:18Z","timestamp":1751365518000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Fosaprepitant for the prevention of multiple-day cisplatin chemotherapy-induced nausea and vomiting: a prospective randomized controlled study"],"prefix":"10.1186","volume":"26","author":[{"given":"Lu","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaowa","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaorong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zewei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanfu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"issue":"6","key":"964_CR1","doi-asserted-by":"publisher","first-page":"100462","DOI":"10.1016\/j.currproblcancer.2019.01.003","volume":"43","author":"Q Li","year":"2019","unstructured":"Li Q, Wu Y, Wang W, et al. Effectiveness and safety of combined neurokinin-1 antagonist aprepitant treatment for multiple-day anthracycline-induced nausea and vomiting. Curr Probl Cancer. 2019;43(6):100462. https:\/\/doi.org\/10.1016\/j.currproblcancer.2019.01.003.","journal-title":"Curr Probl Cancer"},{"key":"964_CR2","doi-asserted-by":"publisher","unstructured":"Li Q, Wang W, Chen G et al. Evaluation of a neurokinin-1 antagonist in preventing multiple-day cisplatin-induced nausea and vomiting. Open Med (Wars). 2018;13:29\u201334. eCollection 2018. https:\/\/doi.org\/10.1515\/med-2018-0005","DOI":"10.1515\/med-2018-0005"},{"key":"964_CR3","doi-asserted-by":"publisher","unstructured":"Costantine Albany MJ, Brames C, Fausel, et al. Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a hoosier oncology group study. J Clin Oncol. 2012;30(32):3998\u20134003. https:\/\/doi.org\/10.1200\/JCO.2011.39.5558. Epub 2012 Aug 20.","DOI":"10.1200\/JCO.2011.39.5558"},{"key":"964_CR4","doi-asserted-by":"publisher","unstructured":"Ng TL, Hutton B, Clemons M. Chemotherapy-Induced nausea and vomiting: time for more emphasis on nausea?Oncologist. 2015;20(6):576\u201383. https:\/\/doi.org\/10.1634\/theoncologist.2014-0438. Epub 2015 May 6.","DOI":"10.1634\/theoncologist.2014-0438"},{"issue":"2","key":"964_CR5","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1515725","volume":"375","author":"RM Navari","year":"2016","unstructured":"Navari RM, Qin R, Ruddy KJ, et al. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting[J]. N Engl J Med. 2016;375(2):134\u201342. https:\/\/doi.org\/10.1056\/NEJMoa1515725.","journal-title":"N Engl J Med"},{"key":"964_CR6","doi-asserted-by":"publisher","unstructured":"Liu G, Jin Y, Jiang Y, et al. A Comparison of the Efficacy of 5\u00a0mg Olanzapine and Aprepitant in the Prevention of Multiple-Day Cisplatin Chemotherapy-Induced Nausea and Vomiting. Int J Clin Pract. 2022;2022(5954379). https:\/\/doi.org\/10.1155\/2022\/5954379.","DOI":"10.1155\/2022\/5954379"},{"issue":"2","key":"964_CR7","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/S1470-2045(19)30678-3","volume":"21","author":"H Hashimoto","year":"2020","unstructured":"Hashimoto H, Abe M, Tokuyama O, et al. Olanzapine 5\u00a0mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21(2):242\u20139. https:\/\/doi.org\/10.1016\/S1470-2045(19)30678-3.","journal-title":"Lancet Oncol"},{"issue":"7","key":"964_CR8","doi-asserted-by":"publisher","first-page":"6225","DOI":"10.1007\/s00520-022-07067-6","volume":"30","author":"J Gao","year":"2022","unstructured":"Gao J, Zhao J, Jiang C, et al. Olanzapine (5\u00a0mg) plus standard triple antiemetic therapy for the prevention of multiple-day cisplatin hemotherapy-induced nausea and vomiting: a prospective randomized controlled study. Supportive Care Cancer: Official J Multinational Association Supportive Care Cancer. 2022;30(7):6225\u201332. https:\/\/doi.org\/10.1007\/s00520-022-07067-6.","journal-title":"Supportive Care Cancer: Official J Multinational Association Supportive Care Cancer"},{"key":"964_CR9","doi-asserted-by":"publisher","unstructured":"Yuanyuan Zhao Y, Yang F, Gao et al. A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial of olanzapine plus triple antiemetic regimen for the prevention of multiday highly emetogenic chemotherapy-induced nausea and vomiting (OFFER study).EClinicalMedicine2022 Dec 15:55:101771. https:\/\/doi.org\/10.1016\/j.eclinm.2022.101771. eCollection 2023 Jan.","DOI":"10.1016\/j.eclinm.2022.101771"},{"issue":"32","key":"964_CR10","doi-asserted-by":"publisher","first-page":"3998","DOI":"10.1200\/JCO.2011.39.5558","volume":"30","author":"MJ Brames","year":"2012","unstructured":"Costantine Albany 1, Brames MJ, Fausel C, Johnson CS, et al. Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a hoosier oncology group study. J Clin Oncol. 2012;30(32):3998\u20134003. Epub 2012 Aug 20.","journal-title":"J Clin Oncol"},{"issue":"3","key":"964_CR11","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s10549-020-05730-2","volume":"182","author":"J Zhang","year":"2020","unstructured":"Zhang J, Lin M, Jin Y, et al. Cisplatin given at three divided doses for three consecutive days in metastatic breast cancer: an alternative schedule for one full dose with comparable effificacy but less CINV and hypomagnesaemia. Breast Cancer Res Treat. 2020;182(3):719\u201326. https:\/\/doi.org\/10.1007\/s10549-020-05730-2. Epub 2020 Jun 10.","journal-title":"Breast Cancer Res Treat"},{"issue":"24","key":"964_CR12","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1097\/CM9.0000000000003442","volume":"137","author":"Y Wu","year":"2024","unstructured":"Wu Y, He S, Cao M, et al. Comparative analysis of cancer statistics in China and the united States in 2024. Chin Med J (Engl). 2024;137(24):3093\u2013100. Epub 2024 Dec 10.","journal-title":"Chin Med J (Engl)"},{"key":"964_CR13","doi-asserted-by":"publisher","unstructured":"Kenneth C, Lasseter J, Gambale B, Jin, et al. Tolerability of fosaprepitant and bioequivalency to aprepitant in healthy subjects. J Clin Pharmacol. 2007;47(7):834\u201340. https:\/\/doi.org\/10.1177\/0091270007301800. Epub 2007 May 24.","DOI":"10.1177\/0091270007301800"},{"issue":"11","key":"964_CR14","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1200\/JCO.2010.31.7859","volume":"29","author":"S Grunberg","year":"2011","unstructured":"Grunberg S, Chua D, Maru A, et al. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol\u2013EASE. J Clin Oncol. 2011;29(11):1495\u2013501. https:\/\/doi.org\/10.1200\/JCO.2010.31.7859.","journal-title":"J Clin Oncol"},{"key":"964_CR15","doi-asserted-by":"publisher","unstructured":"Yilan Jin F, Chen J, Zhao et al. A randomized trial evaluating the association between related gene polymorphism and nausea and vomiting induced by cisplatin multi-day chemotherapy. BMC Medical Genomics (2023) 16:276. 2023;16(1):276. https:\/\/doi.org\/10.1186\/s12920-023-01719-0","DOI":"10.1186\/s12920-023-01719-0"},{"key":"964_CR16","doi-asserted-by":"publisher","first-page":"329","DOI":"10.3389\/fphar.2020.00329","volume":"11","author":"ASM Mosa","year":"2020","unstructured":"Mosa ASM, Hossain AM, Lavoie BJ, et al. Patient-Related risk factors for Chemotherapy-Induced nausea and vomiting: A systematic review. Front Pharmacol. 2020;11:329. https:\/\/doi.org\/10.3389\/fphar.2020.00329.","journal-title":"Front Pharmacol"},{"issue":"4","key":"964_CR17","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s00280-019-03777-7","volume":"83","author":"L Guo","year":"2019","unstructured":"Guo L, Cai HPH-L, et al. Effect of aprepitant administration on CINV caused by cisplatin multi-day chemotherapy and pharmacokinetics of docetaxel. Cancer Chemother Pharmacol. 2019;83(4):727\u201334. https:\/\/doi.org\/10.1007\/s00280-019-03777-7.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"964_CR18","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1200\/JCO.21.01315","volume":"40","author":"IO Akito Hata","year":"2022","unstructured":"Akito Hata IO, Inui N, et al. Randomized, Double-Blind, phase III study of fosnetupitant versus fosaprepitant for prevention of highly emetogenic Chemotherapy-Induced nausea and vomiting: CONSOLE. J Clin Oncol. 2022;40(2):180\u20138. https:\/\/doi.org\/10.1200\/JCO.21.01315. Epub 2021 Nov 18. PMID: 34793245; PMCID: PMC8718175.","journal-title":"J Clin Oncol"},{"key":"964_CR19","doi-asserted-by":"crossref","unstructured":"Tran K, Loshak H. Palonosetron for patients undergoing high or moderate emetogenic chemotherapy [Internet]. Ottawa (ON): Canadian agency for drugs and technologies in health; 2021 Jul. PMID: 36191121.","DOI":"10.51731\/cjht.2021.99"},{"key":"964_CR20","doi-asserted-by":"publisher","unstructured":"Celio L, Agustoni F, Testa I et al. Palonosetron: an evidence-based choice in prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Tumori. 2012 May-Jun;98(3):279\u2013\u200986. PMID: 22825501. https:\/\/doi.org\/10.1177\/030089161209800301","DOI":"10.1177\/030089161209800301"},{"key":"964_CR21","doi-asserted-by":"publisher","unstructured":"Schulz KF, Altman DG, Moher D, et al. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c332. https:\/\/doi.org\/10.1136\/bmj.c332.","DOI":"10.1136\/bmj.c332"},{"issue":"3","key":"964_CR22","doi-asserted-by":"publisher","first-page":"871","DOI":"10.31557\/APJCP.2021.22.3.871","volume":"22","author":"T Terazawa","year":"2021","unstructured":"Fukutaro Shimamoto,Masahiro Goto, Terazawa T, et al. Pharmacokinetics of dexamethasone when administered with fosaprepitant for Chemotherapy-Induced nausea and vomiting and differences in Dose-Dependent antiemetic effects. Asian Pac J Cancer Prev. 2021;22(3):871\u20137. https:\/\/doi.org\/10.31557\/APJCP.2021.22.3.871.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"8","key":"964_CR23","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1007\/s00520-003-0482-4","volume":"11","author":"AR Martin","year":"2003","unstructured":"Martin AR, Pearson JD, Cai B, Elmer M, et al. Assessing the impact of chemotherapy-induced nausea and vomiting on patients\u2019 daily lives: a modifed version of the functional living Index-Emesis (FLIE) with 5-day recall[J]. Support Care Cancer. 2003;11(8):522\u20137. https:\/\/doi.org\/10.1007\/s00520-003-0482-4.","journal-title":"Support Care Cancer"},{"key":"964_CR24","unstructured":"Georgia M, Decker ES, DeMeyer DL, Kisko, et al. Measuring the maintenance of daily life activities using the functional living index-emesis (FLIE) in patients receiving moderately emetogenic chemotherapy[J]. J Support Oncol. 2006;4(1):35\u201341."},{"issue":"10","key":"964_CR25","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1016\/s0959-8049(03)00299-5","volume":"39","author":"AR Martin","year":"2003","unstructured":"Martin AR, Carides AD, Pearson JD, et al. Functional relevance of antiemetic control:experience using the questionnaire in a randomised study of the NK-1 antagonist aprepitant[J]. Eur J Cancer. 2003;39(10):1395\u2013401. https:\/\/doi.org\/10.1016\/s0959-8049(03)00299-5.","journal-title":"Eur J Cancer"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-00964-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-025-00964-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-00964-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T10:25:20Z","timestamp":1751365520000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-025-00964-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["964"],"URL":"https:\/\/doi.org\/10.1186\/s40360-025-00964-6","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"6 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approval by the Ethics Committee of Ordos Central Hospital, Ordos Clinical College of Inner Mongolia Medical University (2020-006). This study was conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Written informed consent was obtained from all patients for publication of this article and any accompanying images. A copy of the written consent is available for review by the editor in chief of this journal.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All listed authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship. All authors have read and approved the submitted version of the manuscript.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship"}}],"article-number":"126"}}